

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/8/2013; Page 1

Suggested Formula	Amphetamine Asparate 2.5 mg/5 mL, Amphetamine Sulfate 2.5 mg/5 mL, Dextroamphetamine Saccharate 2.5 mg/5 mL, Dextroamphetamine Sulfate 2.5 mg/5 mL Oral Suspension (Suspension, 150 mL)	FIN	F 003 206v4
----------------------	---	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Amphetamine Asparate 2.5 mg/Amphetamine Sulfate 2.5 mg/Dextroamphetamine Saccharate 2.5 mg/Dextroamphetamine Sulfate 2.5 mg Tablets	30	Units				
Glycerin, USP	10.0	mL				
Medisca Oral Suspend (Suspending Vehicle)	70.0	mL	®			
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 150.0	mL				

SPECIAL PREPARATORY CONSIDERATIONS

<u>Ingredient-Specific Information</u>		
Controlled substance (adhere a documentation procedures)	to proper handling and	Amphetamine Asparate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate
Hygroscopic (protect from moi	sture whenever possible):	Glycerin
Suggested Preparatory Guidelines		
Non-Sterile Preparat	ion Sterile Preparati	on
<u>Processing Error /</u> <u>Testing Considerations</u> :		g error considerations during preparation, it is suggested to 9% of the required quantities of ingredients.
Special Instruction:	Protective apparel, such as should always be worn.	a lab coat, disposable gloves, eyewear and face-masks
		e use of very small quantities of ingredients. All calculations s must be verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/8/2013; Page 2

Suggested Formula	Amphetamine Asparate 2.5 mg/5 mL, Amphetamine Sulfate 2.5 mg/5 mL, Dextroamphetamine Saccharate 2.5 mg/5 mL, Dextroamphetamine Sulfate 2.5 mg/5 mL Oral Suspension (Suspension, 150 mL)	FIN	F 003 206v4
----------------------	---	-----	-------------

SUGGESTED PREPARATION (for 150 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Amphetamine Asparate 2.5 mg/Amphetamine Sulfate 2.5 mg/Dextroamphetamine Saccharate 2.5 mg/Dextroamphetamine Sulfate 2.5 mg Tablets	30	Units			
Glycerin, USP §	10.0	mL	(6)		
Medisca Oral Suspend (Suspending Vehicle)	70.0	mL	, Y. C.		
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 150.0	mL			

^{*} Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097

technicalservices@medisca.net

10/8/2013; Page 3

	Suggested Formula	Amphetamine Asparate 2.5 mg/5 mL, Amphetamine Sulfate 2.5 mg/5 mL, Dextroamphetamine Saccharate 2.5 mg/5 mL, Dextroamphetamine Sulfate 2.5 mg/5 mL Oral Suspension (Suspension, 150 mL)	FIN	F 003 206v4
--	----------------------	---	-----	-------------

	Preparatory Instruction	
	gredient quantification (determine the actual quantity of Amphetamine/Dextroampheta x to weigh):	amine tablet powder
	Weigh 33 Amphetamine/Dextroamphetamine Tablets. Record the total weight here:	g
B.	Calculate the average weight of powder in each tablet:	•
	Weight of 33 tablets (from Step 1A):	g
	DIVIDED BY	
	Number of tablets:	33
	EQUALS	
	Average weight of a single Amphetamine/Dextroamphetamine Tablet:	g
C.	Calculate the weight of powder equivalent to 30 tablets:	
	Average weight of a single Amphetamine/Dextroamphetamine Tablet (from Step 1B):	g
	MULTIPLED BY	
	Number of tablets required:	30
	EQUALS	
	Weight of powder equivalent to 30 tablets:	g
D.	Calculate the weight of powder required <i>plus</i> processing error adjustments:	
	Weight of powder equivalent to 30 tablets (from Step 1C):	g
	MULTIPLED BY	
	Processing error adjustments (5 to 9%):	1.05 to 1.09
	EQUALS	
	Weight of powder required plus processing error adjustments:	g



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/8/2013; Page 4

Suggested Formula	Amphetamine Asparate 2.5 mg/5 mL, Amphetamine Sulfate 2.5 mg/5 mL, Dextroamphetamine Saccharate 2.5 mg/5 mL, Dextroamphetamine Sulfate 2.5 mg/5 mL Oral Suspension (Suspension, 150 mL)	FIN	F 003 206v4
----------------------	---	-----	-------------

2. **Powder preparation:**

- A. Crush and triturate the 33 Amphetamine/Dextroamphetamine Tablets into a fine homogeneous powder.
- B. Weigh the quantity of Amphetamine/Dextroamphetamine tablet powder mix required for the batch (refer to Step 1D) and discard the remaining powder.

3. **Powder-liquid preparation:**

A. Levigate the Amphetamine/Dextroamphetamine tablet powder mix (amount weighed in Step 2B) with the Glycerin.

End result: Homogeneous paste-like dispersion.

B. Incrementally add the homogeneous paste-like dispersion (Step 3A) to the Oral Suspend (Suspending Vehicle).

Specifications: Continuously mix, using high-shear mixing techniques.

End result: Homogeneous liquid-like dispersion.

4. Filling to volume:

A. Add Oral Syrup (Flavored Vehicle) to the mixture (Step 3B) to fill to the required batch size (150.0 mL *plus* processing error adjustments).

Specifications: Continuously mix, using high-shear mixing techniques.

End result: Homogeneous liquid-like dispersion.

5. **Product transfer:**

A. Transfer the final product into the specified dispensing container (see "Packaging requirements").

<u>Note</u>: Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/8/2013; Page 5

Suggested Formula	Amphetamine Asparate 2.5 mg/5 mL, Amphetamine Sulfate 2.5 mg/5 mL, Dextroamphetamine Saccharate 2.5 mg/5 mL, Dextroamphetamine Sulfate 2.5 mg/5 mL Oral Suspension (Suspension, 150 mL)	FIN	F 003 206v4
----------------------	---	-----	-------------

SUGGESTED PRESENTATION

GGESTED PR	ESE	NIATION					
Estima Beyond-Use D	 Tightly closed dispensing bottle. To be administered with a metered dose-measuring device. 						
	Use as directed. Do not exceed prescribed dose.				Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.		
	2	2 Keep out of reach of children. 7 Cap tightly after use.					
Auxiliary Labels	1 1 Nake well before use						
4 Keep refrigerated. Do not freeze. 9 Controlled substance. Dangerous unled directed.					Controlled substance. Dangerous unless used as directed.		
May impair mental and/or physical ability. Use care when operating a car or machinery. May produce psychological and/or physical ability. dependence.							
Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.							
Patient Instructions	Со	entact your pharmacist in the event	of adverse re	action	ns.		



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/8/2013; Page 6

Suggested Formula	Amphetamine Asparate 2.5 mg/5 mL, Amphetamine Sulfate 2.5 mg/5 mL, Dextroamphetamine Saccharate 2.5 mg/5 mL, Dextroamphetamine Sulfate 2.5 mg/5 mL Oral Suspension (Suspension, 150 mL)	FIN	F 003 206v4
----------------------	---	-----	-------------

REFERENCES

1.	Glycerin. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4th Edition</i> . American Pharmaceutical Association; 2003: 257.
2.	Amphetamine (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #582.
3.	Dextroamphetamine (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #2954.
4.	Dextroamphetamine Sulfate (Monograph). <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 606.
5.	Amphetamine Sulfate (Monograph). <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 148.
6.	USP <795>. United States Pharmacopeia XXVIII / National Formulary 23. Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 2457.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.